These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 21725353)

  • 1. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.
    Spiegel S; Milstien S; Grant S
    Oncogene; 2012 Feb; 31(5):537-51. PubMed ID: 21725353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New endogenous regulators of class I histone deacetylases.
    Riccio A
    Sci Signal; 2010 Jan; 3(103):pe1. PubMed ID: 20051592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
    Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
    Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.
    Mutze K; Langer R; Becker K; Ott K; Novotny A; Luber B; Hapfelmeier A; Göttlicher M; Höfler H; Keller G
    Ann Surg Oncol; 2010 Dec; 17(12):3336-43. PubMed ID: 20585871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
    Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
    Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
    Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
    Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat.
    Zagni C; Floresta G; Monciino G; Rescifina A
    Med Res Rev; 2017 Nov; 37(6):1373-1428. PubMed ID: 28181261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
    Shetty MG; Pai P; Deaver RE; Satyamoorthy K; Babitha KS
    Pharmacol Res; 2021 Aug; 170():105695. PubMed ID: 34082029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring hydroxamic acid inhibitors of HDAC1 and HDAC2 using small molecule tools and molecular or homology modelling.
    Daniel L; Gotsbacher MP; Richardson-Sanchez T; Tieu W; Codd R
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2581-2586. PubMed ID: 31400937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opposed regulation of type I IFN-induced STAT3 and ISGF3 transcriptional activities by histone deacetylases (HDACS) 1 and 2.
    Icardi L; Lievens S; Mori R; Piessevaux J; De Cauwer L; De Bosscher K; Tavernier J
    FASEB J; 2012 Jan; 26(1):240-9. PubMed ID: 21957129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
    Beyer M; Kiweler N; Mahboobi S; Krämer OH
    Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.
    Hait NC; Allegood J; Maceyka M; Strub GM; Harikumar KB; Singh SK; Luo C; Marmorstein R; Kordula T; Milstien S; Spiegel S
    Science; 2009 Sep; 325(5945):1254-7. PubMed ID: 19729656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
    Cai J; Wei H; Hong KH; Wu X; Zong X; Cao M; Wang P; Li L; Sun C; Chen B; Zhou G; Chen J; Ji M
    Bioorg Med Chem; 2015 Jul; 23(13):3457-71. PubMed ID: 25953722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis.
    Jurkin J; Zupkovitz G; Lagger S; Grausenburger R; Hagelkruys A; Kenner L; Seiser C
    Cell Cycle; 2011 Feb; 10(3):406-12. PubMed ID: 21270520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC1 and HDAC2 regulate anti-inflammatory effects of anesthetic isoflurane in human monocytes.
    Guo X; Deng J; Zheng B; Liu H; Zhang Y; Ying Y; Jia J; Ruan X
    Immunol Cell Biol; 2020 Apr; 98(4):318-331. PubMed ID: 31950542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
    Pinkerneil M; Hoffmann MJ; Deenen R; Köhrer K; Arent T; Schulz WA; Niegisch G
    Mol Cancer Ther; 2016 Feb; 15(2):299-312. PubMed ID: 26772204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy.
    Stengel KR; Hiebert SW
    Antioxid Redox Signal; 2015 Jul; 23(1):51-65. PubMed ID: 24730655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
    Khan O; La Thangue NB
    Immunol Cell Biol; 2012 Jan; 90(1):85-94. PubMed ID: 22124371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of histone deacetylases protects septic mice from lung and splenic apoptosis.
    Takebe M; Oishi H; Taguchi K; Aoki Y; Takashina M; Tomita K; Yokoo H; Takano Y; Yamazaki M; Hattori Y
    J Surg Res; 2014 Apr; 187(2):559-70. PubMed ID: 24290430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification and enzymatic assay of class I histone deacetylase enzymes.
    Adams MK; Banks CAS; Miah S; Killer M; Washburn MP
    Methods Enzymol; 2019; 626():23-40. PubMed ID: 31606077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.